secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001600620-23-000030
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia appoints Dr. Karen Smith and Jeffrey A. Bailey to Board; Dr. Daniel G. Billen named Chair
--------------------------------------------------------------------------------

- Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia's Board effective August 18, 2023, bringing decades of biopharma leadership experience.
- Dr. Daniel G. Billen, board member since 2019, appointed Chair of the Board of Directors.
- Both new directors have experience with successful sales, mergers, and partnerships, relevant to the ongoing strategic review process.
- Dr. Smith has served on boards of several acquired companies (Forward Pharma, Sucampo, Acceleron, Antares Pharma).
- Mr. Bailey has held CEO and Chairman roles, including Chairman of Tekla Capital Management since 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/0001600620-23-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/auph-20230818.htm
  HTML page:      https://secwatch.observer/filing/0001600620-23-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer